North America Legal Chronicle. November 17, 2023

Acumen Pharmaceuticals’ Global Collaboration and License Agreement with Halozyme Therapeutics

By Leila Ahmed

Ropes & Gray advised Acumen Pharmaceuticals on the transaction. Acumen Pharmaceuticals (Nasdaq:ABOS) (“Acumen”) announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics (Nasdaq:HALO) (“Halozyme”). Acumen will...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here